Overview

Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell lung cancer. The patients with completely resected stage IB to stage IIIA non-small cell lung cancer were randomly assigned to the group of vinorelbine plus cisplatin plus endostar or to the group of vinorelbine plus cisplatin . The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimens.

Phase:

Phase 3

Details

Lead Sponsor:

Chinese Academy of Sciences

Collaborators:

Beijing Chao Yang Hospital
Chinese Academy of Medical Sciences
Shanghai Jiao Tong University School of Medicine

Treatments:

Cisplatin
Endostatins
Vinblastine
Vinorelbine